Market Exclusive

TELEFLEX INCORPORATED (NYSE:TFX) Files An 8-K Submission of Matters to a Vote of Security Holders

TELEFLEX INCORPORATED (NYSE:TFX) Files An 8-K Submission of Matters to a Vote of Security HoldersItem 5.07.Submission of Matters to a Vote of Security Holders.

(a) The Company held its 2018 annual meeting of stockholders on May 4, 2018 (the “2018 Annual Meeting”). At the 2018 Annual Meeting, the Company’s stockholders voted on:

the election of four directors of the Company to serve for a term of three years and one director for a term of one year or, in each case, until their successors have been duly elected and qualified;

the approval, on an advisory basis, of the compensation of the Company’s named executive officers; and

the ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for 2018.

(b) The final voting results with respect to each proposal are set forth below.

1.Election of Directors

Class of 2021

Name

For

Against

Abstain

Broker Non-Votes

Candace H. Duncan

37,875,601

360,835

57,322

1,979,026

Liam J. Kelly

38,070,318

198,758

24,682

1,979,026

Stephen K. Klasko

36,450,081

1,789,294

54,383

1,979,026

Stuart A. Randle

37,462,411

775,606

55,741

1,979,026

Class of 2019

Name

For

Against

Abstain

Broker Non-Votes

Andrew A. Krakauer

38,065,852

175,244

52,662

1,979,026

2.Advisory Vote on Compensation of Named Executive Officers

For

Against

Abstain

Broker Non-Votes

37,010,060

1,184,636

99,062

1,979,026

3.Ratification of Appointment of Independent Registered Public Accounting Firm

For

Against

Abstain

Broker Non-Votes

39,518,832

709,800

44,152

About TELEFLEX INCORPORATED (NYSE:TFX)
Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company markets and sells its products to hospitals and healthcare providers, across the world, through a combination of its direct sales force and distributors. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM). The Company manufactures its products at approximately 30 manufacturing sites, with manufacturing operations located in the Czech Republic, Germany, Malaysia, Mexico and the United States. The Company’s all others businesses include single-use respiratory, urology and cardiac care products, as well as capital equipment.

Exit mobile version